Versant Capital Management Inc Acquires New Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,964 shares of the company’s stock, valued at approximately $26,000.

A number of other large investors have also modified their holdings of the business. B. Riley Wealth Advisors Inc. acquired a new position in Takeda Pharmaceutical during the third quarter worth about $163,000. Franklin Resources Inc. purchased a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $244,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $40,000. World Investment Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the third quarter valued at approximately $258,000. Finally, Sanctuary Advisors LLC lifted its position in Takeda Pharmaceutical by 100.9% during the third quarter. Sanctuary Advisors LLC now owns 70,021 shares of the company’s stock worth $937,000 after buying an additional 35,161 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.35 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The stock’s fifty day moving average is $13.51 and its two-hundred day moving average is $13.89. The firm has a market capitalization of $42.48 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.